Salvia

Salvia operates as a sophisticated Family Office headquartered in Holzkirchen, a picturesque town in the vicinity of Munich, Germany. What began as a traditional family investment vehicle has strategically transformed into a dynamic venture capital investor with an entrepreneurial mindset. The firm leverages its independent financial position and long-term investment horizon to make decisions unencumbered by typical fund structures or limited partner pressures. This autonomy allows Salvia to pursue opportunities with greater flexibility and patience than conventional venture capital entities.

The investment philosophy at Salvia centers primarily on breakthrough innovations emerging from the deep-tech and scientific research sectors. Their portfolio reflects a particular interest in companies developing transformative technologies with substantial intellectual property and significant barriers to entry. Salvia demonstrates a preference for startups addressing complex technical challenges in fields such as advanced materials, quantum computing, biotechnology, medical devices, and other frontier technologies that require specialized knowledge to evaluate properly.

Unlike many investors who prioritize quick returns, Salvia embraces the extended development cycles inherent in deep-tech ventures. The firm provides not just financial capital but also strategic guidance, industry connections, and operational expertise to its portfolio companies. This comprehensive support system helps scientific founders navigate the challenging journey from laboratory innovation to commercial viability. Salvia's investment team combines backgrounds in both technical disciplines and business management, enabling them to effectively evaluate and nurture scientifically complex startups through various growth stages.

The German investor has established itself as a trusted partner within the European deep-tech ecosystem, with particular strength in the DACH region (Germany, Austria, and Switzerland). While maintaining a primary focus on early-stage investments, Salvia occasionally participates in later funding rounds for portfolio companies demonstrating exceptional progress. Their investment approach emphasizes quality over quantity, typically making fewer but more substantial commitments than comparable venture firms, and maintaining active involvement with each portfolio company. This selective strategy allows Salvia to provide meaningful support to entrepreneurs tackling some of the world's most challenging scientific and technological problems.